Petadolex supplement by
Ray Sahelian, M.D.
October 20 2016
Petadolex is made by Weber and Weber GmbH and Co. Petadolex is a patented, standardized CO2 rhizome root extraction of Petasites marketed in Europe since 1992. I searched in Feb 2014 on Medline and could not find any new studies.
As of 2016, I have not come across recent studies with the branded product.
Enzymatic Therapy, Petadolex, Pro-Active, 60 Softgels
Buy Petadolex supplement - Enzymatic Therapy
Buy Petadolex supplement
|Serving Size: 1 softgel|
|Amount per softgel||% DV|
(Petasites hybridus) (Petadolex brand) Root Extract standardized to contain 7.5 mg petasins and to be free of harmful levels of pyrrolizidine alkaloids (PAs)
|**Daily Value not established.|
Recommendations: One butterbur softgel three times daily, or 2 softgels 2 times daily for the first four weeks. Thereafter, one softgel twice daily.
Petadolex nutritional supplement contains the patented extract of butterbur that supports healthy blood vessel tone in the brain, as well as normal blood flow in the brain.* Butterbur has been the subject of several placebo-controlled clinical studies.
Petadolex is standardized to contain 15% of butterbur's key ingredient, petasin. It's also guaranteed to be pyrrolizidine alkaloid (PA) free, so you can use it with confidence. PA's are toxic compounds that can harm the liver. Studies demonstrate patented it is safe and well tolerated.
Petadolex for asthma
Petasites hybridus (Butterbur root) extract in the treatment of asthma--an open trial.
Altern Med Rev. 2004. University of Heidelberg, Germany.
The efficacy and tolerability of a butterbur root extract Petadolex for the treatment of asthma was analyzed in a prospective, non-randomized, open trial. Subjects included 64 adults and 16 children/adolescents treated for two months with the extract, followed by two months during which the intake of the extract was optional. Concomitant asthma medication was permitted. The number, duration, and severity of asthma attacks decreased, while peak flow, forced expiratory volume, and all measured symptoms improved during Petadolex therapy. In addition, more than 40 percent of patients using asthma medications at baseline reduced intake of these medications by the end of the study. This study suggests the Petasites hybridus extract Petadolex is an effective and safe therapy for the treatment of asthma.
Petadolex for migraine
Butterbur root extract Petadolex and music therapy in the prevention of childhood migraine: an explorative study.
Eur J Pain. 2008. Department of Child and Adolescent Psychiatry, University of Heidelberg, Heidelberg, Germany.
This study was to assess efficacy of a butterbur root extract Petadolex and music therapy in primary school children with migraine. Following a 8-week baseline patients were randomized and received either Petadolex, music therapy, or placebo over 12 weeks. During post-treatment, only music therapy was superior to placebo, whereas in the follow-up period both music therapy and Petadolex were superior to placebo. All groups showed a substantial reduction of attack frequency already during baseline. Petadolex and music therapy might be superior to placebo and may represent promising treatment approaches in the prophylaxis of pediatric migraine.
Effectiveness of Petasites hybridus preparations in
the prophylaxis of migraine: a systematic review.
Phytomedicine. 2006. Headache Center Hirslanden, Zürich, Switzerland.
The objective of this review was to evaluate the strength of evidence of effectiveness for Petasites hybridus in the prophylaxis of migraine. Several databases and other sources were searched to identify randomised-controlled trials investigating Petasites hybridus preparations. Two trials totalling 293 patients (60 and 233 patients) were included in this review. Both trials investigated the proprietary Petasites root extract Petadolex. The extract at higher dose (150 mg) showed a greater decreased frequency of migraine attacks and a greater number of responders (improvement>50%) after treatment over 3-4 months than the extract at lower dose (100 mg) and placebo. Moderate evidence of effectiveness is, thus, available for a higher than the recommended dose of the proprietary Petasites root extract Petadolex in the prophylaxis of migraine.